Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

MiR-641 participates in the progression of breast cancer by modulation of RELN expression

Ruixin Qu, Yaoqiang Wu, Daxin Chen, Feng Jiang

Department of General Surgery, Dandong First Hospital, Dandong, China;

For correspondence:- Feng Jiang Email: jf13942511107@163.com Tel:+8613942511107

Accepted: 6 January 2022 Published: 31 January 2022

Citation: Qu R, Wu Y, Chen D, Jiang F. MiR-641 participates in the progression of breast cancer by modulation of RELN expression. Trop J Pharm Res 2022; 21(1):37-43 doi: 10.4314/tjpr.v21i1.7

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To examine the role of micro-ribonucleic acid 641 (miR-641) in breast cancer, and to uncover its possible molecular mechanism.

Methods: MiR-641 expressions in breast cancer cell lines and tissues were determined using Real-time fluorescence quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and the diagnostic potential value of miR-641 was assessed using receiver operating characteristic (ROC) curves. The survival of the patients was analyzed using Kaplan-Meier, and the cell viability and migration capacity were evaluated using Transwell and cell counting kit-8 (CCK-8) assay, and the downstream target gene of miR-641 was confirmed via dual-luciferase reporter gene assay. Finally, reversal assay was employed to corroborate the molecular mechanism that affects cell proliferation and migration via modulation of RELN.

Results: MiR-641 was lowly expressed in breast cancer cell lines and tissues, and its expression in the metastasizing group was lower than that in the matched group (p < 0.05). It was also observed that miR-641 expression gradually decreased as the breast cancer advanced. Moreover, lower miR-641 expression revealed a poor prognosis, and up-regulating miR-641 suppressed the proliferative and migrative capacities of breast cancer cells. It was proven that RELN is a target gene of miR-641. RELN expression rose in breast cancer, and it was evidently and negatively correlated with that of miR-641. Finally, miR-641 regulated RELN, and it affected the proliferation and migration of cells.

Conclusion: MiR-641 has an obviously decreased expression level in breast cancer, and facilitates the proliferative and migrative capacity of breast cancer cells probably by modulating the RELN expression. This study may provide new targets for the treatment of breast cancer.

Keywords: Breast cancer, REELIN, micro-ribonucleic acid 641, Proliferation, Migration